# Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma

> **NCT00005590** · PHASE3 · COMPLETED · sponsor: **Cancer Research Campaign Clinical Trials Centre**

## Conditions studied

- Brain and Central Nervous System Tumors
- Breast Cancer
- Extragonadal Germ Cell Tumor
- Infection
- Lung Cancer
- Lymphoma
- Ovarian Cancer
- Small Intestine Cancer
- Testicular Germ Cell Tumor
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** levofloxacin

## Key facts

- **NCT ID:** NCT00005590
- **Lead sponsor:** Cancer Research Campaign Clinical Trials Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-08
- **Primary completion:** —
- **Final completion:** 2005-09
- **Target enrollment:** — (—)
- **Last updated:** 2013-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005590, "Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00005590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*